Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - Performance obligations (Details)

v3.21.2
Revenue - Collaboration Agreement - Performance obligations (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
item
Astellas Collaboration Agreement    
Performance obligations    
Number of independent targets | item   2
Amount of transaction price allocated to performance obligation that has not been recognized as revenue $ 65,414 $ 65,414
Astellas Collaboration Agreement | Rights granted, first independent target    
Performance obligations    
Amount of transaction price allocated to performance obligation that has not been recognized as revenue 15,400 15,400
Astellas Collaboration Agreement | Rights granted, second independent target    
Performance obligations    
Amount of transaction price allocated to performance obligation that has not been recognized as revenue 15,400 15,400
GSK Collaboration And License Agreement    
Performance obligations    
Revenue recognized in the period   536
Milestone payments received 4,200  
Revenue recognised from partially satisfied performane obligation in previous periods $ 1,029 $ 1,029